199 related articles for article (PubMed ID: 19012295)
41. Synthesis and secondary structure in membranes of the Bcl-2 anti-apoptotic domain BH4.
Khemtémourian L; Sani MA; Bathany K; Gröbner G; Dufourc EJ
J Pept Sci; 2006 Jan; 12(1):58-64. PubMed ID: 15948141
[TBL] [Abstract][Full Text] [Related]
42. Designed high affinity Cu2+-binding alpha-helical foldamer.
Nicoll AJ; Miller DJ; Fütterer K; Ravelli R; Allemann RK
J Am Chem Soc; 2006 Jul; 128(28):9187-93. PubMed ID: 16834392
[TBL] [Abstract][Full Text] [Related]
43. Fragment-based deconstruction of Bcl-xL inhibitors.
Barelier S; Pons J; Marcillat O; Lancelin JM; Krimm I
J Med Chem; 2010 Mar; 53(6):2577-88. PubMed ID: 20192224
[TBL] [Abstract][Full Text] [Related]
44. Chimeric (alpha/beta + alpha)-peptide ligands for the BH3-recognition cleft of Bcl-XL: critical role of the molecular scaffold in protein surface recognition.
Sadowsky JD; Schmitt MA; Lee HS; Umezawa N; Wang S; Tomita Y; Gellman SH
J Am Chem Soc; 2005 Aug; 127(34):11966-8. PubMed ID: 16117535
[TBL] [Abstract][Full Text] [Related]
45. Structural characterization of a neurotoxic threonine-rich peptide corresponding to the human prion protein alpha 2-helical 180-195 segment, and comparison with full-length alpha 2-helix-derived peptides.
Ronga L; Palladino P; Saviano G; Tancredi T; Benedetti E; Ragone R; Rossi F
J Pept Sci; 2008 Oct; 14(10):1096-102. PubMed ID: 18563793
[TBL] [Abstract][Full Text] [Related]
46. Synthetic peptides mimicking the interleukin-6/gp130 interaction: a two-helix bundle system. Design and conformational studies.
Zaccaro L; Bucci E; Vitale RM; Perretta G; Fattorusso R; Benedetti E; Saviano M; Pedone C
J Pept Sci; 2003 Feb; 9(2):90-105. PubMed ID: 12630694
[TBL] [Abstract][Full Text] [Related]
47. Identification of lead compounds as antagonists of protein Bcl-xL with a diversity-oriented multidisciplinary approach.
Di Micco S; Vitale R; Pellecchia M; Rega MF; Riva R; Basso A; Bifulco G
J Med Chem; 2009 Dec; 52(23):7856-67. PubMed ID: 19852471
[TBL] [Abstract][Full Text] [Related]
48. Solution structure of human BCL-w: modulation of ligand binding by the C-terminal helix.
Denisov AY; Madiraju MS; Chen G; Khadir A; Beauparlant P; Attardo G; Shore GC; Gehring K
J Biol Chem; 2003 Jun; 278(23):21124-8. PubMed ID: 12651847
[TBL] [Abstract][Full Text] [Related]
49. Analysis of peptide design in four-, five-, and six-helix bundle template assembled synthetic protein molecules.
Seo ES; Sherman JC
Biopolymers; 2007; 88(5):774-9. PubMed ID: 17554752
[TBL] [Abstract][Full Text] [Related]
50. Adsorption behavior of linear and cyclic genetically engineered platinum binding peptides.
Seker UO; Wilson B; Dincer S; Kim IW; Oren EE; Evans JS; Tamerler C; Sarikaya M
Langmuir; 2007 Jul; 23(15):7895-900. PubMed ID: 17579466
[TBL] [Abstract][Full Text] [Related]
51. Comparative biophysical characterization of p53 with the pro-apoptotic BAK and the anti-apoptotic BCL-xL.
Sot B; Freund SM; Fersht AR
J Biol Chem; 2007 Oct; 282(40):29193-200. PubMed ID: 17699158
[TBL] [Abstract][Full Text] [Related]
52. Structural constraints imposed by the conserved fusion peptide on the HIV-1 gp41 epitope recognized by the broadly neutralizing antibody 2F5.
de la Arada I; Julien JP; de la Torre BG; Huarte N; Andreu D; Pai EF; Arrondo JL; Nieva JL
J Phys Chem B; 2009 Oct; 113(41):13626-37. PubMed ID: 19754136
[TBL] [Abstract][Full Text] [Related]
53. A putative role for human BFK in DNA damage-induced apoptosis.
Ozören N; Inohara N; Núñez G
Biotechnol J; 2009 Jul; 4(7):1046-54. PubMed ID: 19557800
[TBL] [Abstract][Full Text] [Related]
54. A blue-green absorbing cross-linker for rapid photoswitching of peptide helix content.
Chi L; Sadovski O; Woolley GA
Bioconjug Chem; 2006; 17(3):670-6. PubMed ID: 16704204
[TBL] [Abstract][Full Text] [Related]
55. Structural basis of Bcl-xL recognition by a BH3-mimetic α/β-peptide generated by sequence-based design.
Lee EF; Smith BJ; Horne WS; Mayer KN; Evangelista M; Colman PM; Gellman SH; Fairlie WD
Chembiochem; 2011 Sep; 12(13):2025-32. PubMed ID: 21744457
[TBL] [Abstract][Full Text] [Related]
56. Dynamical binding of hydrogen-bond surrogate derived Bak helices to antiapoptotic protein Bcl-xL.
Bao J; Dong XY; Zhang JZ; Arora PS
J Phys Chem B; 2009 Mar; 113(11):3565-71. PubMed ID: 19231824
[TBL] [Abstract][Full Text] [Related]
57. Deciphering the antitumoral activity of quinacrine: Binding to and inhibition of Bcl-xL.
Orzáez M; Mondragón L; García-Jareño A; Mosulén S; Pineda-Lucena A; Pérez-Payá E
Bioorg Med Chem Lett; 2009 Mar; 19(6):1592-5. PubMed ID: 19237284
[TBL] [Abstract][Full Text] [Related]
58. Structure-activity relationships of a peptidic antagonist of Id1 studied by biosensor method, circular dichroism spectroscopy, and bioassay.
Yang SY; Chen Y; Yang CX; Yang DL; Kuo SC; Huang LJ; Lung FD
J Pept Sci; 2011 Oct; 17(10):667-74. PubMed ID: 21805537
[TBL] [Abstract][Full Text] [Related]
59. Structural analysis of peptides that interact with Newcastle disease virus.
Chia SL; Tan WS; Shaari K; Abdul Rahman N; Yusoff K; Satyanarayanajois SD
Peptides; 2006 Jun; 27(6):1217-25. PubMed ID: 16377031
[TBL] [Abstract][Full Text] [Related]
60. Structural insights into mouse anti-apoptotic Bcl-xl reveal affinity for Beclin 1 and gossypol.
Priyadarshi A; Roy A; Kim KS; Kim EE; Hwang KY
Biochem Biophys Res Commun; 2010 Apr; 394(3):515-21. PubMed ID: 20206602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
